Beijing Langzhen Pharmaceutical Technology

Beijing Langzhen Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases and oncology, leveraging its internal research capabilities to advance a pipeline of novel chemical entities and high-end complex generics. Its lead candidate, LZ001, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical development for the treatment of hyperuricemia and gout. Langzhen is supported by prominent Chinese venture capital firms and operates out of the Daxing Bio-Medicine Industry Park. The company aims to improve patient outcomes by providing high-quality, cost-effective pharmaceutical solutions for the global market.